OTCQB: GTBP

Immunotherapy for the Treatment of Cancer

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.

View Product Pipeline

About

GT Biopharma, Inc. a targeted immunotherapies company with close to market treatments for Central Nervous System diseases.

About

Latest News

GT Biopharma Announces Closing of Private Placement Financing and Provides Business Update
Feb 6, 2019 • 4:01 EST | Read More

GT Biopharma, Inc. to Present at Biotech Showcase™ 2019
Dec 20, 2018 • 8:22 EST | Read More

Investors

GT Biopharma, Inc. OTCQB: GTBP
Loading... Change
Loading... Volume
Loading... 52 Week Range